Open Account
العربية
Open Account

ImmunityBio Announces Insurance Coverage of ANKTIVA Across Multiple States With First Commercial Doses Administered

ImmunityBio Inc Ordinary Shares -2.91% Post

ImmunityBio Inc Ordinary Shares

IBRX

0.00

  • Multiple patients treated across the U.S. with ANKTIVA less than eight weeks after FDA approval of first-in-class cytokine immunotherapy for BCG unresponsive non-muscle invasive bladder cancer
  • ANKTIVA launch initiates the next era of immunotherapy beyond checkpoint inhibitors that is based on cytokines and natural killer (NK) cells
  • ANKTIVA's novel mechanism of action activates the body's immune system of natural killer and killer T cells to attack BCG resistant tumor cells and induce memory T cells resulting in a long duration of complete response exceeding 47 months1
  • ANKTIVA reimbursement now covered by multiple healthcare plans
  • Urologists treating eligible bladder cancer patients can learn more about the treatment option and access support program ImmunityBio CARE™ at Anktiva.com
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via